Thrombolysis for acute ischemic stroke

Current Topics in Medicinal Chemistry

Volumn 9, Issue 14, 2009, Pages 1285-1290

  Uyttenboogaart, M ^a   De Keyser, J ^a,b   Luijckx, G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DESMOTEPLASE; HEPARIN; STREPTOKINASE; TENECTEPLASE; UROKINASE;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; FIBRINOLYSIS; HEMATOMA; HUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; RECANALIZATION; REVIEW; STROKE PATIENT;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FIBRINOLYSIS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 74249105594     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789869655     Document Type: Review

References (57)

1. The WHO world health report 2002. http: //www. who. int/topics/ cerebrovascular-accident/en/
2. Pulsinelli, W. Pathophysiology of acute ischaemic stroke. Lancet 1992, 339, 533-6.
3. Suenson, E.; Thorsen, S. The course and prerequisites of Lysplasminogen formation during fibrinolysis. Biochemistry 1988, 27, 2435-43.
4. Thorsen, S.; Philips, M.; Selmer, J.; Lecander, I.; Astedt, B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur. J. Biochem. 1988, 175, 33-9.
5. Plow, E.F.; Felez, J.; Miles, L.A. Cellular regulation of fibrinolysis. Thromb. Haemost. 1991, 66, 32-6.
6. Kaur, J.; Zhao, Z.; Klein, G.M.; Lo, E.H.; Buchan, A.M. The neurotoxicity of tissue plasminogen activator? J. Cereb. Blood Flow Metab. 2004, 24, 945-63.
7. Wilczak, N.; Elting, J.W.; Chesik, D.; Kema, I.P.; De Keyser, J. Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1. Stroke 2006, 37, 2368-71.
8. Donnan, G.A.; Davis, S.M.; Chambers, B.R.; Gates, P.C.; Hankey, G.J.; McNeil, J.J.; Rosen, D.; Stewart-Wynne, E.G.; Tuck, R.R. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996, 276, 961-6.
9. Multicentre Acute Stroke Trial--Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995, 346, 1509-14.
10. The Multicenter Acute Stroke Trial--Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N. Engl. J. Med. 1996, 335, 145-50.
11. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995, 333, 1581-7.
12. Hacke, W.; Kaste, M.; Fieschi, C.; Toni, D.; Lesaffre, E.; von Kummer, R.; Boysen, G.; Bluhmki, E.; Hoxter, G.; Mahagne, M.H.; Hennerici, M. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274, 1017-25.
13. Hacke, W.; Kaste, M.; Fieschi, C.; von Kummer, R.; Davalos, A.; Meier, D.; Larrue, V.; Bluhmki, E.; Davis, S.; Donnan, G. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998, 352, 1245-51.
14. Clark, W.M.; Wissman, S.; Albers, G.W.; Jhamandas, J.H.; Madden, K.P.; Hamilton, S.; for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999, 282, 2019-26.
15. Hacke, W.; Donnan, G.; Fieschi, C.; Kaste, M.; von Kummer, R.; Broderick, J.P.; Brott, T.; Frankel, M.; Grotta, J.C.; Haley, E.C.; Jr. , Kwiatkowski, T.; Levine, S.R.; Lewandowski, C.; Lu, M.; Lyden, P.; Marler, J.R.; Patel, S.; Tilley, B.C.; Albers, G.; Bluhmki, E.; Wilhelm, M.; Hamilton, S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363, 768-74.
16. Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Davalos, A.; Guidetti, D.; Larrue, V.; Lees, K.R.; Medeghri, Z.; Machnig, T.; Schneider, D.; von Kummer, R.; Wahlgren, N.; Toni, D. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N. Engl. J. Med. 2008, 359, 1317-29.
17. Del Zoppo, G.J.; Saver, J.L.; Jauch, E.C.; Adams, H.P.; Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009, 40, 2945-8.
18. Davis, S.M.; Donnan, G.A.; Parsons, M.W.; Levi, C.; Butcher, K.S.; Peeters, A.; Barber, P.A.; Bladin, C.; De Silva, D.A.; Byrnes, G.; Chalk, J.B.; Fink, J.N.; Kimber, T.E.; Schultz, D.; Hand, P.J.; Frayne, J.; Hankey, G.; Muir, K.; Gerraty, R.; Tress, B.M.; Desmond, P.M. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008, 7, 299-309.
19. Albers, G.W.; Thijs, V.N.; Wechsler, L.; Kemp, S.; Schlaug, G.; Skalabrin, E.; Bammer, R.; Kakuda, W.; Lansberg, M.G.; Shuaib, A.; Coplin, W.; Hamilton, S.; Moseley, M.; Marks, M.P. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann. Neurol. 2006, 60, 508-17.
20. Kohrmann, M.; Juttler, E.; Fiebach, J.B.; Huttner, H.B.; Siebert, S.; Schwark, C.; Ringleb, P.A.; Schellinger, P.D.; Hacke, W. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol. 2006, 5, 661-7.
21. Uyttenboogaart, M.; Luijckx, G.J.; Kappelle, L.J.; van Oostenbrugge, R.J.; Dippel, D.W.; Stam, J. Treatment of acute ischemic stroke with intravenous thrombolysis: extension of the time window should not delay initiation of treatment. Ned. Tijdschr. Geneeskd. 2008, 152, 2653-5.
22. Albers, G.W.; Bates, V.E.; Clark, W.M.; Bell, R.; Verro, P.; Hamilton, S.A. Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study. JAMA 2000, 283, 1145-50.
23. Grotta, J.C.; Burgin, W.S.; El Mitwalli, A.; Long, M.; Campbell, M.; Morgenstern, L.B.; Malkoff, M.; Alexandrov, A.V. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch. Neurol. 2001, 58, 2009-13.
24. Grond, M.; Stenzel, C.; Schmulling, S.; Rudolf, J.; Neveling, M.; Lechleuthner, A.; Schneweis, S.; Heiss, W.D. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998, 29, 1544-9.
25. Wahlgren, N.; Ahmed, N.; Davalos, A.; Ford, G.A.; Grond, M.; Hacke, W.; Hennerici, M.G.; Kaste, M.; Kuelkens, S.; Larrue, V.; Lees, K.R.; Roine, R.O.; Soinne, L.; Toni, D.; Vanhooren, G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007, 369, 275-82.
26. Uyttenboogaart, M.; Vroomen, P.C.; Stewart, R.E.; De Keyser, J.; Luijckx, G.J. Safety of routine IV thrombolysis between 3 and 4. 5 h after ischemic stroke. J. Neurol. Sci. 2007, 254, 28-32.
27. Hill, M.D.; Buchan, A.M. Thrombolysis for acute ischemic stroke: results of the canadian alteplase for stroke effectiveness study. CMAJ 2005, 172, 1307-12.
28. Katzan, I.L.; Furlan, A.J.; Lloyd, L.E.; Frank, J.I.; Harper, D.L.; Hinchey, J.A.; Hammel, J.P.; Qu, A.; Sila, C.A. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000, 283, 1151-8.
29. Tanne, D.; Bates, V.E.; Verro, P.; Kasner, S.E.; Binder, J.R.; Patel, S.C.; Mansbach, H.H.; Daley, S.; Schultz, L.R.; Karanjia, .P.N.; Scott, P.; Dayno, J.M.; Vereczkey-Porter, K.; Benesch, C.; Book, D.; Coplin, W.M.; Dulli, D.; Levine, S.R. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 1999, 53, 424-7.
30. Wang, D.Z.; Rose, J.A.; Honings, D.S.; Garwacki, D.J.; Milbrandt, J.C. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 2000, 31, 77-81.
31. Egan, R.; Lutsep, H.L.; Clark, W.M.; Quinn, J.; Kearns, K.; Lockfeld, A.; Ireland, S.; Goins, S.; Buchholz, G. Open label tissue plasminogen activator for stroke: The oregon experience. J. Stroke Cerebrovasc. Dis. 1999, 8, 287-90.
32. Lindsberg, P.J.; Soinne, L.; Roine, R.O.; Salonen, O.; Tatlisumak, T.; Kallela, M.; Happola, O.; Tiainen, M.; Haapaniemi, E.; Kuisma, M.; Kaste, M. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003, 34, 1443-9.
33. Hacke, W.; Albers, G.; Al Rawi, Y.; Bogousslavsky, J.; Davalos, A.; Eliasziw, M.; Fischer, M.; Furlan, A.; Kaste, M.; Lees, K.R.; Soehngen, M.; Warach, S.; for The DIAS Study Group. The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005, 36, 66-73.
34. Furlan, A.J.; Eyding, D.; Albers, G.W.; Al Rawi, Y.; Lees, K.R.; Rowley, H.A.; Sachara, C.; Soehngen, M.; Warach, S.; Hacke, W. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006, 37, 1227-31.
35. Hacke, W.; Furlan, A.J.; Al Rawi, Y.; Davalos, A.; Fiebach, J.B.; Gruber, F.; Kaste, M.; Lipka, L.J.; Pedraza, S.; Ringleb, P.A.; Rowley, H.A.; Schneider, D.; Schwamm, L.H.; Leal, J.S.; Sohngen, M.; Teal, P.A.; Wilhelm-Ogunbiyi, K.; Wintermark, M.; Warach, S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009, 8, 141-50.
36. Parsons, M.W.; Miteff, F.; Bateman, G.A.; Spratt, N.; Loiselle, A.; Attia, J.; Levi, C.R. Acute ischemic stroke: Imaging-guided tenecteplase treatment in an extended time window. Neurology 2009, 72, 915-21.
37. Furlan, A.; Higashida, R.; Wechsler, L.; Gent, M.; Rowley, H.; Kase, C.; Pessin, M.; Ahuja, A.; Callahan, F.; Clark, W.M.; Silver, F.; Rivera, F.; for the PROACT Investigators. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II Study: A Randomized Controlled Trial. JAMA 1999, 282, 2003-11.
38. del Zoppo, G.J.; Higashida, R.T.; Furlan, A.J.; Pessin, M.S.; Rowley, H.A.; Gent, M. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998, 29, 4-11.
39. Ogawa, A.; Mori, E.; Minematsu, K.; Taki, W.; Takahashi, A.; Nemoto, S.; Miyamoto, S.; Sasaki, M.; Inoue, T. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007, 38, 2633-9.
40. IMS Study investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004, 35, 904-11.
41. IMS Study investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007, 38, 2127-35.
42. Lewandowski, C.A.; Frankel, M.; Tomsick, T.A.; Broderick, J.; Frey, J.; Clark, W.; Starkman, S.; Grotta, J.; Spilker, J.; Khoury, J.; Brott, T. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: emergency management of stroke (EMS) bridging trial. Stroke 1999, 30, 2598-605.
43. O'Connor, R.E.; McGraw, P.; Edelsohn, L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann. Emerg. Med. 1999, 33, 9-14.
44. Boiten, J.; Wilmink, J.T.; Lodder, J.; Troost, J. Thrombolytic therapy in patients with acute brain infarction: favorable preliminary results in Maastricht. Ned. Tijdschr. Geneeskd. 2000, 144, 1062-9.
45. Barber, P.A.; Zhang, J.; Demchuk, A.M.; Hill, M.D.; Buchan, A.M. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001, 56, 1015-20.
46. Katzan, I.L.; Hammer, M.D.; Hixson, E.D.; Furlan, A.J.; bou-Chebl, A.; Nadzam, D.M. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch. Neurol. 2004, 61, 346-50.
47. Cocho, D.; Belvis, R.; Marti-Fabregas, J.; Molina-Porcel, L.; az-Manera, J.; Aleu, A.; Pagonabarraga, J.; Garcia-Bargo, D.; Mauri, A.; Marti-Vilalta, J.L. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005, 64, 719-20.
48. Bray, J.E.; Coughlan, K.; Bladin, C. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern. Med. J. 2006, 36, 483-8.
49. Huang, P.; Chen, C.H.; Yang, Y.H.; Lin, R.T.; Lin, F.C.; Liu, C.K. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor. Cerebrovasc. Dis. 2006, 22, 423-8.
50. Garcia-Monco, J.C.; Pinedo, A.; Escalza, I.; Ferreira, E.; Foncea, N.; Gomez-Beldarrain, M.; Ruiz-Ojeda, J.; Mateo, I.; Mediavilla, J.; Basterretxea, J.M. Analysis of the reasons for exclusion from tPA therapy after early arrival in acute stroke patients. Clin. Neurol. Neurosurg. 2007, 109, 50-3.
51. Boode, B.; Welzen, V.; Franke, C.; van Oostenbrugge, R. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc. Dis. 2007, 23, 294-8.
52. Engelter, S.T.; Gostynski, M.; Papa, S.; Ajdacic-Gross, V.; Lyrer, P.A. Barriers to stroke thrombolysis in a geographically defined population. Cerebrovasc. Dis. 2007, 23, 211-5.
53. Hills, N.K.; Johnston, S.C. Why are eligible thrombolysis candidates left untreated? Am. J. Prev. Med. 2006, 31, S210-S216.
54. Dirks, M.; Niessen, L.W.; Koudstaal, P.J.; Franke, C.L.; van Oostenbrugge, R.J.; Dippel, D.W. Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contra-indications. An international Delphi study. J. Neurol. Neurosurg. Psychiatry 2007, 78(7), 685-9.
55. Uyttenboogaart, M.; Koch, M.W.; Koopman, K.; Vroomen, P.C.; De Keyser, J.; Luijckx, G.J. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch. Neurol. 2008, 65, 607-11.
56. Demchuk, A.M.; Morgenstern, L.B.; Krieger, D.W.; Linda Chi, T.; Hu, W.; Wein, T.H.; Hardy, R.J.; Grotta, J.C.; Buchan, A.M. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999, 30, 34-9.
57. Tanne, D.; Kasner, S.E.; Demchuk, A.M.; Koren-Morag, N.; Hanson, S.; Grond, M.; Levine, S.R. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice the multicenter rt-PA acute stroke survey. Circulation 2002, 105, 1679-85.